Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery
Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to demonstrate the benefit of Pemigatinib, a drug that
has indicated promising effects for relapse free survival in molecularly-selected, high-risk
patients with urothelial carcinoma (UC) who have received radical surgery. Patients will
receive Pemigatinib at a once-daily dose on a continuous schedule, continued until 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
European Association of Urology Research Foundation
Collaborators:
AMS Advanced Medical Services GmbH High Research s.r.l. Incyte Biosciences International Sàrl